Welcome to our dedicated page for PFIZER SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pfizer Inc. filings document the financial, governance, capital-structure, and material-event disclosures of a global biopharmaceutical company. The company's 8-K reports include quarterly operating results, financial guidance updates, Regulation FD disclosures, clinical or regulatory disclosure categories, material agreements, and other corporate events tied to its medicines, vaccines, pipeline, and commercial organization.
Pfizer's proxy and annual-meeting filings cover board elections, auditor ratification, executive compensation, shareholder voting results, and equity-plan governance. Its capital markets filings and 8-K exhibits also disclose common stock, NYSE-listed notes, shelf registration activity, public debt offerings, note maturities, and related capital-structure terms.
Pfizer Inc. reported that Chairman and CEO Albert Bourla received a grant of 708,666 stock appreciation rights on March 3, 2026. These rights were acquired as a grant or award, not through open-market purchases.
According to the disclosure, the stock appreciation rights are subject to vesting conditions and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. After this transaction, Bourla held a total of 708,666 stock appreciation rights directly.
BOSHOFF CHRISTOFFEL reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. reported that President of R&D Christoffel Boshoff received a grant of 259,844 stock appreciation rights on March 3, 2026. These derivative awards carry no purchase price and are part of his equity-based compensation.
The stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date, aligning the executive’s potential reward with long-term company performance.
Pfizer Inc. reported that Chief Financial Officer and EVP David M. Denton received a grant of 216,537 Stock Appreciation Rights on March 3, 2026. These awards were acquired at a stated price of $0.00 per right, reflecting an equity-based compensation grant rather than an open-market purchase.
The footnote explains that the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. Following this grant, Denton’s reported direct derivative holdings in these rights total 216,537.
Pfizer Inc. Executive Vice President Douglas M. Lankler reported an acquisition of 194,883 stock appreciation rights on March 3, 2026. These derivative awards carry no exercise price and are scheduled to be settled in Pfizer common stock on the fifth anniversary of the grant date, subject to vesting conditions.
MALIK AAMIR reported acquisition or exercise transactions in this Form 4 filing.
Pfizer executive vice president Aamir Malik received a grant of 194,883 stock appreciation rights on March 3, 2026. These derivative awards were granted at no cost and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant, subject to vesting requirements.
Baum Andrew reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Executive Vice President Andrew Baum reported an equity compensation grant in the form of 303,151 stock appreciation rights. These stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.
Pfizer Inc. Executive Vice President Lidia Fonseca reported receiving a grant of 82,284 stock appreciation rights on Pfizer common stock. These rights were acquired as a compensation award at a price of $0.0000 per right and are held as direct ownership.
According to the disclosure, the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. After this grant, Fonseca held a total of 82,284 stock appreciation rights.
Pfizer Inc. Executive Vice President Michael McDermott received a grant of 151,576 Stock Appreciation Rights on March 3, 2026. These rights were acquired at a price of $0.00 per right as a form of equity-based compensation.
According to the disclosure, the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. After this grant, McDermott directly holds 151,576 stock appreciation rights.
SAHNI PAYAL reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Executive Vice President Payal Sahni received a grant of 108,268 stock appreciation rights. These derivative awards were granted at a price of $0.00 per right and are scheduled to be settled in shares of Pfizer common stock on the fifth anniversary of the grant date, subject to vesting requirements.
de Germay Alexandre reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Executive Vice President Alexandre de Germay received a grant of 194,883 stock appreciation rights on Pfizer common stock. These rights were awarded at no purchase price and are classified as a derivative security. According to the terms, the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.